Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study)

Puntos clave

• This research aims to evaluate dapagliflozin's usage and treatment practices in heart failure patients.
• Large non-interventional study
• 1-year follow-up in Central Eastern Europe and the Baltic region
• Assessment of guideline-directed medical therapy
• High persistence rates of dapagliflozin observed
• Low proportion of patients received complete guideline-directed medical therapy
• Need for improved heart failure management decisions indicated